ClinicalTrials.gg
Active, not recruitingNCT06071091PISTARUpdated Jan 9, 2024

Permanent Intracranial Stenting for Acute Ischemic Stroke Related to a Refractory Large Vessel Occlusion

An interventional study of Intracranial stenting and Optimal medical care, without additional endovascular procedures in Acute Ischemic Stroke, sponsored by Assistance Publique - Hôpitaux de Paris. Active, not recruiting at 13 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-09.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
346
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Ischemic Stroke by Assistance Publique - Hôpitaux de Paris — 9 open to participants now, 11 under way, 4 of them phase 3. Ischemic Stroke · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
9th of 14
346 · median 487
Started
2023
with 6 others
No phase
4 of 20
1 open now
Primary completion
2027-02
later than 3 of 10 live
Registered
17th of 20
by date

Among the 20 studies in Ischemic Stroke by Assistance Publique - Hôpitaux de Paris, this one is the 9th largest by planned enrollment of the 14 interventional ones that give a count, is one of 7 that started in 2023, is one of 4 with no phase, reaches primary completion later than 3 of the 10 other live ones, and was the 17th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

9 of the 20 studies in Ischemic Stroke by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Ischemic Stroke by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Clot extraction failure during mechanical thrombectomy is a major concern in the management of acute ischemic stroke related to large vessel occlusions. Indeed, it can occur in up to 10 to 30% of cases and, therefore, is associated with a very poor prognosis. These refractory occlusions frequently occur when an underlying intracranial atherosclerotic disease is present. Thus, one of the most promising rescue technique consists of placing a permanent intracranial stent, under dual antiplatelet therapy over the target refractory occlusion. This strategy is well studied in coronary occlusions where the atheroscotic mechanism is highly prevalent. However, as the ischemiated brain is at much higher risk of hemorrhagic complications, such strategy entails a greater risk. This raises the question of whether such risk is worth the reward of obtaining reperfusion. The investigators designed this randomized study in order to evaluate whether a strategy combining rescue pemanent intracranial stenting with the best medical treatment is superior to the best medical treatment alone in acute refractory large vessel occlusions.

Read the detailed description

These past recent years, mechanichal thrombectomy has become the standard treatment for acute ischemic strokes due to large vessel occlusions. Mechanical thrombectomy failure occurs in about 10 to 30% of cases with disastrous consequences for these patients. Indeed, reperfusion failures are associated with 30.5% mortality rates and only 21% of all patients are able to achieve functional independence at 3 months.

In order to treat these refractory large vessel occlusions many techniques and devices have been developped. Rescue Intracranial Stenting (RIS) is the most studied technique and the most promising one. However, RIS requires strong antithrombotic medications to ensure stent patency, which may increase the risk of hemorrhagic complications.

The investigators recently performed a meta-analysis of observational data, that showed that RIS in refractory large vessel occlusions allowed significant improvements in functional outcome at 3 months. The rate of good functional outcome at 3 months went from 21% in the control group (no RIS) to 43% in the RIS group. Mortality was also significantly reduced from 30.5% (control group) to 18.8% in the RIS group. Furthermore, RIS did not increase the rate of symptomatic intracranial hemorrhage.

Of course, this meta-analysis is only based on observational data and needs to be confirmed in a randomized trial to bring the highest level of evidence.

Refractory large vessel occlusions are commonly caused by an underlying intracranial atherosclerotic plaque. Since the SAMMPRIS trial, most of the indications for the endovascular treatment of intracranial atherosclerotic stenoses have been removed. Nevertheless, there are subsets of patients who actually benefit from intracranial stenting such as patients with refractory large vessel occlusions or patients with hemodynamically significant stenoses. As such, the PISTAR trial could be a way of validating intracranial stenting in this indication.

All patients admitted for a mechanical thrombectomy will be screened before the procedure. If the patient fulfills the preoperative elligibility criteria, she/he will be informed of the possibility of being included in case of a refractory occlusion. If the patients' clinical state does not allow her/him to give informed consent, she/he can still be included using an emergency consent procedure. Consents to pursue the study will be sought as soon as possible, from the patient or her/his trusted relative.

If the patient meets all remaining elligibility criteria during the mechanical thrombectomy in particular if the occlusion is considered as refractory, she/he can be included and randomized.

Randomization will be performed using a minimization procedure based on the recruiting center, the administration of IV thrombolysis and the location of the occlusion (anterior versus posterior circulation). The randomzation will be centralized using an online e-crf platform.

The patient can be randomized in one of the two following arms

  • Intervention arm : RIS + best medical treatment In this arm, a dedicated antithrombotic protocol will be initiated before the deployment of the stent. The choice of antithrombotics and the need to perform additional endovascular manœuvres such as balloon angioplasty will be left at the operator's discretion. A standard protocol for antithrombotics is proposed.
  • Control arm : best medical treatment with no additional thrombectomy passes In this arm, the procedure is stopped and a last control angiogram is performed to confirm the absence of reperfusion. Any additional medical treatment is allowed.

Follow up visits will be performed immediately after the procedure (V0), at 24hrs (V1), 72hs (V2) and 1 month (V3). The end-research visit will be performed at 3 months (+/- 15 days) and a remote safety visit will be performed at 6 months.

03

Conditions studied

  • Acute Ischemic Stroke

Keywords

  • Brain
  • Intracranial
  • Ischemia
  • Stroke
  • Mechanical Thrombectomy
  • Intracranial Occlusion
  • Refractory Occlusion
  • Interventional
  • Angioplasty
  • Stenting
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age>18 years
  • Acute ischemic stroke secondary to an occlusion of the internal carotid artery termination OR the 1st or 2nd segment of the middle cerebral artery OR the basilar artery and/or the 4th segment of the vertebral artery radiologically proven (CT Angiography or angio-MRI)
  • Patient within the authorised timeframe for a MT, according to the AHA/ASA 2019 grade I recommendations
  • intracranial large vessel occlusion defined as :

Persistent arterial occlusion (mTICI 0 or I) after a minimum of 3 mechanical thrombectomy passes using direct aspiration or a stent retriever OR Early arterial reocclusion (\<10 minutes) after at least one pass OR Underlying stenosis (estimated between 70 and 99%)

  • ASPECT Score for CT or DWI-ASPECTS for MRI or pc(-DWI)- ASPECTS (posterior circulation) ≥ 5
  • Independent patient before stroke (mRS 0-2)
  • Patient's or her/his trusted relative's consent or emergency procedure consent

Exclusion criteria

Exclusion Criteria:

  • Proximal intracranial vascular occlusion not confirmed on angiography
  • Intracranial bleeding \<3 months or intracranial bleeding during TM procedure prior to inclusion
  • to a dual antiplatelet therapy
  • Mechanical thrombectomy procedure requiring carotid or vertebral arterial access by direct puncture
  • Proof of significant ischemic lesions in a vascular territory not affected by the occlusion
  • Proven allergy to iodinated contrast material
  • Patient known for severe renal impairment with \< 30ml/min
  • Pregnant or breastfeeding women
  • Tandem occlusion (defined as the association of an intracranial occlusion to a cervical steno-occlusive lesion on the same arterial axis that needs additional endovascular manœuvers for the cervical lesion)
  • Major comorbidities that could hinder the improvement or the follow up of the patient or the benefit of the intervention
  • Unaffiliation to the French Social Security system
  • Patient under juridic protection
  • Patient participating in another interventional trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
346 participants (estimated)

Study arms

  • Experimental
    Intracranial stenting

    Rescue Intracranial Stenting + best medical treatment

    Device: Intracranial stenting

  • Active comparator
    Best medical management alone

    Best medical treatment with no additional thrombectomy passes

    Other: Optimal medical care, without additional endovascular procedures

Interventions

  • DeviceIntracranial stenting

    In order to promote the efficacy of the stent to reopen the target vessel, there are two requirments prior stenting: First, balloon angioplasty can be performed at operators' discretion based on angiographic findings. Second, a dual antiplatelet therapy protocol is considered essential to maintain stent patency, and therefore should be introduced before stent implantation whenever possible. Permanent Intracranial can then be performed according to the standard technique: An autoexpandable intracranial stent (Neuroform Atlas 4x24mm) is deployed though a dedicated microcatheter over the target refractory occlusion The only stent system allowed is the Neuroform Atlas 4x24mm (Stryker Neurovascular) The anti-thrombotic drugs used, their route of administration, the choice of navigation equipment are left to the discretion of the team in charge of the patient. A standardized anti-thrombotic protocol will be proposed as an indication.

  • OtherOptimal medical care, without additional endovascular procedures

    The control group represents the standard therapeutic strategy for refractory vascular occlusions, which consists of stopping the procedure without performing any additional mechanical thrombectomy attempts. In this group, the procedure will be stopped after randomization and a control seriography will be performed to confirm the persistent nature of the intracranial occlusion. The patient will benefit from the best medical care available, which may include any medical treatment including a dual anti-platelet therapy if the therapeutic team deems it necessary (Standard medical care may also include (non-exhaustive list): * Nursing * Nursing care * Symptomatic treatments: analgesics for example * Systematic clinical monitoring and control imaging if necessary * Rehabilitation if necessary)

06

What researchers measure

Primary outcomes

  1. Rate of independent patients

    Rate of independent patients at 3 months, defined as a modified Rankin Scale (mRS) 0-2, evaluated by a trained health professional, blinded to the randomization arm. Min=0 ; Max=6 (lower is better)

    Time frame: 3 months

Secondary outcomes

  1. Mortality

    Mortality rate at 6 months

    Time frame: 6 months

  2. Excellent functional outcome

    Rate of excellent functional prognosis defined as a modified Rankin Scale (mRS) score of 0-1 at 3 months Min=0 ; Max=6 (lower is better)

    Time frame: 3 months

  3. modified Rankin Scale (mRS)

    Distribution of mRS scores at 3 months Min=0 ; Max=6 (lower is better)

    Time frame: 3 months

  4. Successful reperfusion

    Successful reperfusion rate (Score modified Thrombolysis In Cerebral Infarction \[mTICI\] ≥IIb) Min=0 ; Max=3 (higher is better)

    Time frame: End of procedure (up to 4 hours)

  5. Excellent reperfusion

    Excellent reperfusion rate (defined as modified Thrombolysis In Cerebral Infarction \[mTICI\] score ≥IIc) Min=0 ; Max=3 (higher is better)

    Time frame: End of procedure (up to 4 hours)

  6. Symptomatic ischemic recurrence

    Rate of symptomatic ischemic recurrence (≥4 points of National Institutes of Health Stroke Scale (NIHSS) compared to the lowest NIHSS score during management) certified by imaging within 3 months. Min=0 ; Max=42 (lower is better)

    Time frame: 3 months

  7. Rate of patients requiring a new mechanical thrombectomy

    Rate of patients requiring a new mechanical thrombectomy within the group of patients with symtomatic ischemic recurrence

    Time frame: 3 months

  8. Neurologic recovery

    Neurologic recovery at 24 hours, according to the National Institutes of Health Stroke Scale (NIHSS) score as compared to initial NIHSS score Min=0 ; Max=42 (lower is better)

    Time frame: 24 hours

  9. Neurologic recovery

    Neurologic recovery at 72 hours, according to the National Institutes of Health Stroke Scale (NIHSS) score as compared to initial NIHSS score Min=0 ; Max=42 (lower is better)

    Time frame: 72 hours

  10. Periprocedural time (time between arterial puncture and successful reperfusion (if obtained))

    Time between arterial puncture and successful reperfusion (if obtained)

    Time frame: End of procedure (up to 4 hours)

  11. Periprocedural time (Time between onset of symptoms (or "last seen normal") and successful reperfusion (if obtained))

    Time between onset of symptoms (or "last seen normal") and successful reperfusion (if obtained)

    Time frame: End of procedure (up to 4 hours)

  12. Periprocedural time (Time between randomization and successful reperfusion (if obtained))

    Time between randomization and successful reperfusion (if obtained)

    Time frame: End of procedure (up to 4 hours)

  13. Procedure duration

    Time between arterial puncture and arterial closure

    Time frame: End of procedure (up to 4 hours)

  14. Intracranial hemorrhagic complications

    Rate of symptomatic intracranial haemorrhage at 6 months defined as any intracranial haemorrhage responsible for neurological deterioration (≥4 NIHSS points compared to the lowest NIHSS score during management)

    Time frame: 6 months

  15. Distribution of intracranial hemorrhagic complications

    Distribution of intracranial hemorrhagic complications according to the Heidelberg classification

    Time frame: 6 months

  16. Serious extracranial hemorrhagic complications

    Rate of serious extra-cranial hemorrhagic complications at 6 months, defined as any extra-cranial bleeding complication requiring re-hospitalization and/or surgery and/or blood transfusion

    Time frame: 6 months

  17. All procedural complications

    Rate of all procedural complications, including vascular perforation, dissection, embolism in a territory not previously affected by the ischemia and serious complications on the arterial access (as defined below)

    Time frame: Up to 6 months

  18. Vascular perforation

    Rate of vascular perforation during the procedure

    Time frame: End of procedure (up to 4 hours)

  19. Dissection

    Rate of dissection during the procedure

    Time frame: End of procedure (up to 4 hours)

  20. Embolism in a territory not previously affected by the ischemia

    Rate of embolism in a territory not previously affected by the ischemia, during the procedure

    Time frame: End of procedure (up to 4 hours)

  21. Serious complication on the arterial access

    Rate of serious complications on the arterial access, defined as any superficial hematoma with deglobulisation \[loss of 2 Hb points on the NFS\] and/or requiring a transfusion, retroperitoneal hematoma with or without deglobulisation, arterial pseudo-aneurysm at the puncture site requiring surgical treatment, femoral artery occlusion and/or acute limb ischemia, puncture site abscess.

    Time frame: 6 months

  22. Vascular reocclusion

    Rate of vascular reocclusion on 24-hour imaging

    Time frame: 24 hours

  23. Adverse events

    Rate of adverse events at 6 months

    Time frame: 6 months

  24. Serious adverse events

    Rate of serious adverse events at 6 months

    Time frame: 6 months

07

Study locations

13 sites
08

References and documents

Individual participant data

Plan to share: Yes — Data are available upon reasonable request. The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor

Access criteria: Researchers who provide a methodologically sound proposal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Feb 2027, 38 months after the start.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 38 months is above that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2023
First posted
Oct 6, 2023
StartActual
Nov 8, 2023
Primary completionEst.
Feb 1, 2027
CompletionEst.
Aug 1, 2027
Last update
Jan 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06071091
Responsible party
Sponsor
First posted
Oct 6, 2023
Start date
Nov 8, 2023
Primary completion
Feb 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Jan 9, 2024

Study contacts

Kevin PREMAT, MD
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion